<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Haematol</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Haematol</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1365-2141</journal-id><journal-id journal-id-type="publisher-id">BJH</journal-id><journal-title-group><journal-title>British Journal of Haematology</journal-title></journal-title-group><issn pub-type="ppub">0007-1048</issn><issn pub-type="epub">1365-2141</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25640315</article-id><article-id pub-id-type="pmc">4737113</article-id><article-id pub-id-type="doi">10.1111/bjh.13239</article-id><article-id pub-id-type="publisher-id">BJH13239</article-id><article-categories><subj-group subj-group-type="overline"><subject>Research Paper</subject></subj-group><subj-group subj-group-type="heading"><subject>Transplantation</subject></subj-group></article-categories><title-group><article-title>A comparative study of reduced dose alemtuzumab in matched unrelated donor and related donor reduced intensity transplants</article-title><alt-title alt-title-type="left-running-head">L. Jardine <italic>et&#x000a0;al</italic></alt-title></title-group><contrib-group><contrib id="bjh13239-cr-0001" contrib-type="author"><name><surname>Jardine</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="bjh13239-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="bjh13239-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="bjh13239-cr-0002" contrib-type="author"><name><surname>Publicover</surname><given-names>Amy</given-names></name><xref ref-type="aff" rid="bjh13239-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="bjh13239-cr-0003" contrib-type="author"><name><surname>Bigley</surname><given-names>Venetia</given-names></name><xref ref-type="aff" rid="bjh13239-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="bjh13239-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="bjh13239-cr-0004" contrib-type="author"><name><surname>Hale</surname><given-names>Geoff</given-names></name><xref ref-type="aff" rid="bjh13239-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="bjh13239-cr-0005" contrib-type="author"><name><surname>Pearce</surname><given-names>Kim</given-names></name><xref ref-type="aff" rid="bjh13239-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="bjh13239-cr-0006" contrib-type="author"><name><surname>Dickinson</surname><given-names>Anne</given-names></name><xref ref-type="aff" rid="bjh13239-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="bjh13239-cr-0007" contrib-type="author"><name><surname>Jackson</surname><given-names>Graham</given-names></name><xref ref-type="aff" rid="bjh13239-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="bjh13239-cr-0008" contrib-type="author" corresp="yes"><name><surname>Collin</surname><given-names>Matthew</given-names></name><xref ref-type="aff" rid="bjh13239-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="bjh13239-aff-0002">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="bjh13239-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Institute of Cellular Medicine</named-content><institution>Newcastle University</institution><named-content content-type="city">Newcastle upon Tyne</named-content><country country="GB">UK</country></aff><aff id="bjh13239-aff-0002"><label><sup>2</sup></label><institution>Newcastle upon Tyne Hospitals NHS Foundation Trust</institution><named-content content-type="city">Newcastle upon Tyne</named-content><country country="GB">UK</country></aff><aff id="bjh13239-aff-0003"><label><sup>3</sup></label><institution>University Hospital Southampton</institution><named-content content-type="city">Southampton</named-content><country country="GB">UK</country></aff><aff id="bjh13239-aff-0004"><label><sup>4</sup></label><institution>Mablyte Ltd</institution><named-content content-type="city">Reading</named-content><country country="GB">UK</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label>
Correspondence: Professor Matthew Collin, Human Dendritic Cell Laboratory, Institute of Cellular Medicine, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK.<break/>
E&#x02010;mail: <email>matthew.collin@newcastle.ac.uk</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>1</month><year>2015</year></pub-date><pub-date pub-type="ppub"><month>3</month><year>2015</year></pub-date><volume>168</volume><issue>6</issue><issue-id pub-id-type="doi">10.1111/bjh.2015.168.issue-6</issue-id><fpage>874</fpage><lpage>881</lpage><history><date date-type="received"><day>23</day><month>7</month><year>2014</year></date><date date-type="accepted"><day>15</day><month>10</month><year>2014</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2015 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2015 The Authors. <italic>British Journal of Haematology</italic> Published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:BJH-168-874.pdf"/><abstract id="bjh13239-abs-0001"><title>Summary</title><p>
<italic>In vivo</italic> T cell depletion with 100&#x000a0;mg alemtuzumab prevents graft&#x02010;versus&#x02010;host disease (<styled-content style="fixed-case">GVHD</styled-content>) in reduced intensity conditioned transplants but is associated with delayed immune reconstitution, a higher risk of infection and relapse. De&#x02010;escalation studies have shown that a reduced dose of 30&#x000a0;mg is as effective as 100&#x000a0;mg in preventing <styled-content style="fixed-case">GVHD</styled-content> in matched related donor (<styled-content style="fixed-case">MRD</styled-content>) transplants. Dose reduction in matched unrelated donor (<styled-content style="fixed-case">MUD</styled-content>) transplants is feasible but the comparative efficacy of alemtuzumab in this setting is not known and opinions vary widely concerning the optimal level of <styled-content style="fixed-case">GVHD</styled-content> prophylaxis that should be achieved. Through retrospective analysis we made an objective comparison of <styled-content style="fixed-case">MUD</styled-content> transplants receiving an empirically reduced dose of 60&#x000a0;mg, with <styled-content style="fixed-case">MRD</styled-content> transplants receiving a 30&#x000a0;mg dose. We observed proportionate levels of alemtuzumab according to dose but an inverse relationship with body surface area particularly in <styled-content style="fixed-case">MRD</styled-content> transplants. <styled-content style="fixed-case">MUD</styled-content> transplants experienced more acute and chronic <styled-content style="fixed-case">GVHD</styled-content>, higher T cell chimerism, more sustained use of ciclosporin and less need for donor lymphocyte infusion than <styled-content style="fixed-case">MRD</styled-content> transplants. Thus, doubling the dose of alemtuzumab to 60&#x000a0;mg did not provide equivalent prevention of <styled-content style="fixed-case">GVHD</styled-content> after <styled-content style="fixed-case">MUD</styled-content> transplant although there was no difference in non&#x02010;relapse mortality or survival compared with <styled-content style="fixed-case">MRD</styled-content> transplants.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="bjh13239-kwd-0001">bone marrow transplantation</kwd><kwd id="bjh13239-kwd-0002">T cell depletion</kwd><kwd id="bjh13239-kwd-0003">graft&#x02010;versus&#x02010;host disease</kwd></kwd-group><funding-group><award-group><funding-source>Wellcome Trust</funding-source><award-id>WT097941</award-id><award-id>WT101155/Z/13/Z</award-id></award-group></funding-group><funding-group><award-group><funding-source>Bright Red</funding-source><award-id>1105891</award-id></award-group></funding-group><counts><page-count count="8"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>bjh13239</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>March 2015</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.7.5 mode:remove_FC converted:26.01.2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Alemtuzumab (CAMPATH 1H), a humanised immunoglobulin G1 (IgG1) monoclonal antibody against CD52, is a well&#x02010;established agent for effecting <italic>in vivo</italic> T cell depletion in the setting of allogeneic haematopoietic stem cell transplantation. By reducing the number of both donor and recipient T cells, it allows engraftment, while reducing the incidence of acute and chronic graft&#x02010;versus&#x02010;host disease (GVHD) (Kottaridis <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0017" ref-type="ref">2000</xref>; Chakraverty <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0007" ref-type="ref">2002</xref>). Conventional alemtuzumab dosing (100&#x000a0;mg in five daily doses of 20&#x000a0;mg) has been shown to ablate acute and chronic GVHD almost completely in fludarabine and melphalan (FM) conditioned matched related donor (MRD) and matched unrelated donor (MUD) transplants (Kottaridis <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0017" ref-type="ref">2000</xref>; Chakraverty <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0007" ref-type="ref">2002</xref>). Subsequent studies have reported lower rates of chronic GVHD with equivalent overall survival compared with GVHD prophylaxis with methotrexate or mycophenolate mofetil (Perez&#x02010;Simon <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0026" ref-type="ref">2002</xref>; Delgado <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0009" ref-type="ref">2008</xref>; van Besien <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0003" ref-type="ref">2009</xref>; Malladi <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0020" ref-type="ref">2009</xref>). This is achieved, however, at the expense of delayed immune reconstitution (Morris <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0023" ref-type="ref">2003</xref>; Dodero <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0010" ref-type="ref">2005</xref>), an increase in opportunistic infections (Chakrabarti <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0005" ref-type="ref">2002a</xref>,<xref rid="bjh13239-bib-0006" ref-type="ref">b</xref>; Perez&#x02010;Simon <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0026" ref-type="ref">2002</xref>; Avivi <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0001" ref-type="ref">2004</xref>) and higher incidence of mixed chimerism, which may impair graft&#x02010;versus&#x02010;leukaemia responses (Mackinnon <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0019" ref-type="ref">1994</xref>).</p><p>The risks of T cell depletion can be ameliorated by donor lymphocyte infusions (DLIs) (Peggs <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0024" ref-type="ref">2004</xref>, <xref rid="bjh13239-bib-0025" ref-type="ref">2007</xref>; Bloor <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0004" ref-type="ref">2008</xref>; Thomson <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0033" ref-type="ref">2010</xref>; Mohamedbhai <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0022" ref-type="ref">2012</xref>; Liga <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0018" ref-type="ref">2013</xref>) but there is a need to define minimum levels of T cell depletion that provide effective protection from GVHD in different settings. A formal dose de&#x02010;escalation study in MRD transplants concluded that a single alemtuzumab dose of 30&#x000a0;mg on day &#x02212;1 is sufficient to prevent GVHD (Chakraverty <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0008" ref-type="ref">2010</xref>) but equivalent studies in MUD transplants are lacking. Favourable outcomes have been reported in mixed cohorts of MRD and MUD transplants for a wide range of alemtuzumab doses from 50&#x000a0;mg to as little as 10&#x000a0;mg (Faulkner <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0012" ref-type="ref">2004</xref>; Khouri <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0016" ref-type="ref">2004</xref>; Tholouli <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0032" ref-type="ref">2008</xref>; Bertz <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0002" ref-type="ref">2009</xref>; Spyridonidis <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0031" ref-type="ref">2011</xref>; Gartner <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0014" ref-type="ref">2013</xref>; Potter <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0027" ref-type="ref">2014</xref>). These are difficult to interpret: first, they involve mixed cohorts of MRD and MUD transplants; and second, the definition of &#x02018;adequate&#x02019; control of GHVD is entirely subjective with some centres tolerating much higher rates of acute GVHD and extensive chronic GVHD than others.</p><p>In the absence of a formal de&#x02010;escalation study in MUD transplants and lack of rational criteria to define adequate GVHD prophylaxis, we compared an empirically reduced dose of 60&#x000a0;mg alemtuzumab in MUD transplants, with 30&#x000a0;mg for MRD transplants, previously defined by formal study (Chakraverty <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0008" ref-type="ref">2010</xref>). This offers an objective assessment of the potential of alemtuzumab to modify unrelated donor alloreactivity, relative to the level of a sibling donor.</p><sec id="bjh13239-sec-0002"><title>Methods</title><sec id="bjh13239-sec-0003"><title>Study design and ethics</title><p>The study included sequential patients transplanted with FM conditioning, following the introduction of de&#x02010;escalated alemtuzumab dosing for MRD and MUD transplants in 2006. Clinical records were interrogated for GVHD, survival, chimerism testing and ciclosporin levels. All patients gave consent for clinical follow&#x02010;up and post&#x02010;transplant serum sampling for research purposes, according to protocols approved by the local research ethics committee of Northumberland and North Tyneside.</p></sec><sec id="bjh13239-sec-0004"><title>Conditioning regimen and alemtuzumab dosing</title><p>All patients received fludarabine 30&#x000a0;mg/m<sup>2</sup> per day from day &#x02212;7 to &#x02212;3 and melphalan 140&#x000a0;mg/m<sup>2</sup> day &#x02212;2. Alemtuzumab 30&#x000a0;mg was given on day &#x02212;2 for MRD transplants and on days &#x02212;4 and &#x02212;2 for MRD transplants (total 60&#x000a0;mg). Day &#x02212;2 was preferred rather than day &#x02212;1 because kinetic studies indicated a steep decline in levels in the first 24&#x000a0;h after infusion (Morris <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0023" ref-type="ref">2003</xref>). We reasoned that the timing of stem cell infusion, which is not well controlled, would have less effect on the level of T cell depletion if we allowed 48&#x000a0;h following alemtuzumab adminstration, at which point alemtuzumab levels would be more stable. A minimum CD34<sup>+</sup> stem cell dose of 4&#x000a0;&#x000d7;&#x000a0;10<sup>6</sup>/kg was infused in all patients. Historical patients treated with 100&#x000a0;mg of alemtuzumab received 20&#x000a0;mg daily from day &#x02212;7 to &#x02212;3, inclusive.</p></sec><sec id="bjh13239-sec-0005"><title>Post&#x02010;transplant monitoring and management</title><p>Graft&#x02010;versus&#x02010;host disease prophylaxis was ciclosporin given at 2&#x000b7;5&#x000a0;mg/kg twice daily from day &#x02212;1 (with a target of 200&#x02013;300&#x000a0;&#x003bc;g/l). Ciclosporin levels were monitored twice weekly by enzyme&#x02010;linked immunosorbent assay. Tapering began at day +30 in the absence of GVHD. All patients received chemoprophylaxis against <italic>Pneumocystis jirovecii</italic> and Varicella Zoster. Serum cytomegalovirus (CMV) copy number was assessed twice weekly by polymerase chain reaction (PCR) and pre&#x02010;emptive therapy was initiated if copy number rose above &#x0003e;10<sup>4</sup>. Peripheral blood and bone marrow chimerism was tested by short tandem repeat PCR on unfractionated bone marrow and magnetically&#x02010;selected CD3<sup>+</sup> and CD15<sup>+</sup> fractions of peripheral blood. Monitoring took place monthly until day +100 and 3&#x02010;monthly thereafter. A schedule of DLIs, escalating by half&#x02010;log increments every 3&#x000a0;months was instituted for persistent partial chimerism, beginning at 3&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup>/kg at 6&#x000a0;months. Patients with early relapse received 10&#x02010;fold higher doses at 4&#x02013;6 weekly intervals. Clinical assessment of acute GVHD was performed at least once weekly in the first 100&#x000a0;d using modified Glucksberg criteria (Hunt <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0015" ref-type="ref">2001</xref>). Incidence of chronic GVHD was assessed at 1&#x000a0;year post&#x02010;transplant and graded using both Seattle and National Institutes of Health criteria (Shulman <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0030" ref-type="ref">1980</xref>; Filipovich <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0013" ref-type="ref">2005</xref>). Body surface area was estimated by the method of Dubois (Dubois &#x00026; Dubois, <xref rid="bjh13239-bib-0011" ref-type="ref">1916</xref>).</p></sec><sec id="bjh13239-sec-0006"><title>Serum alemtuzumab measurement</title><p>Post&#x02010;transplant serum samples were available from 20 MRD&#x000a0;recipients and 13 MUD recipients at day +1 and 11 MRD recipients and nine MUD recipients at day 3&#x02013;4. Alemtuzumab&#x000a0;concentration was measured as previously described by a validated flow cytometry assay (Rebello &#x00026; Hale, <xref rid="bjh13239-bib-0028" ref-type="ref">2002</xref>).</p></sec><sec id="bjh13239-sec-0007"><title>Statistical methods</title><p>Intergroup analyses were performed with Student's <italic>t</italic> test for continuous variables, Mann&#x02013;Whitney test for proportions and Chi&#x02010;square for contingency. The three group&#x02010;comparison of serum alemtuzumab levels used one&#x02010;way analysis of variance (<sc>anova</sc>). Multiple <italic>t</italic>&#x02010;tests used for intergroup analysis of serum ciclosporin levels over time were subjected to sequential Bonferroni correction. Overall survival was analysed by the Kaplan Meier method with log&#x02013;rank test to compare survival curves. Relapse and non&#x02010;relapse mortality were analysed by the cumulative incidence method with relapse as a competing event for non&#x02010;relapse mortality (NRM) and vice&#x02010;versa. Cumulative incidence curves were compared with Gray's test. Hazard ratios were calculated by Cox Regression modelling. Graphing and statistical analyses were performed with <sc>graphpad prism</sc> version 6.0 (GraphPad Software, Inc. La Jolla, CA, USA) except for cumulative incidence, which was performed with <sc>r</sc> version 3.1.0 and Cox Regression, which was performed with <sc>spss</sc> version 21 (IBM United Kingdom Ltd., Portsmouth, UK). <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0&#x000b7;05 was recorded as significant.</p></sec></sec><sec id="bjh13239-sec-0008"><title>Results</title><sec id="bjh13239-sec-0009"><title>Patient characteristics</title><p>From May 2006 to May 2009, 24 patients received MRD transplants and 19 received MUD transplants. Over this period a total of 51 patients were transplanted with reduced intensity conditioning (Fig&#x000a0;<xref rid="bjh13239-fig-0001" ref-type="fig">1</xref>). Eight were not included in the study because they were transplanted with different doses of alemtuzumab (two MRD and two MUD transplants) or the MUD transplants were less than 9/10 human leucocyte antigen (HLA)&#x02010;matched (four patients). Patients included in the study were well matched for age, transplant indication and donor/recipient CMV status (Table&#x000a0;<xref rid="bjh13239-tbl-0001" ref-type="table-wrap">1</xref>). All MRD recipients were 12/12 HLA&#x02010;matched. Seventeen of the unrelated donors&#x000a0;were 10/10 matched at high resolution. Two donors were 9/10 matched due to single allele mismatches in HLA&#x02010;Cw.</p><table-wrap id="bjh13239-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Patient characteristics</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Patient baseline data</th><th align="left" valign="top" rowspan="1" colspan="1">FMA 30 <italic>n</italic>&#x000a0;=&#x000a0;24</th><th align="left" valign="top" rowspan="1" colspan="1">FMA 60 <italic>n</italic>&#x000a0;=&#x000a0;19</th><th align="left" valign="top" rowspan="1" colspan="1">
<italic>P</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age at transplant (years), mean&#x000a0;&#x000b1;&#x000a0;SEM</td><td align="left" rowspan="1" colspan="1">45&#x000a0;&#x000b1;&#x000a0;1&#x000b7;3</td><td align="left" rowspan="1" colspan="1">48&#x000a0;&#x000b1;&#x000a0;2&#x000b7;9</td><td align="left" char=" " rowspan="1" colspan="1">ns</td></tr><tr><td align="left" colspan="4" rowspan="1">Gender direction of transplant <italic>n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Male to male</td><td align="left" char=" " rowspan="1" colspan="1">8 (33)</td><td align="left" char=" " rowspan="1" colspan="1">10 (53)</td><td align="left" char=" " rowspan="4" colspan="1">ns</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Male to female</td><td align="left" char=" " rowspan="1" colspan="1">6 (25)</td><td align="left" char=" " rowspan="1" colspan="1">6 (32)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Female to male</td><td align="left" char=" " rowspan="1" colspan="1">7 (29)</td><td align="left" char=" " rowspan="1" colspan="1">1 (5)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Female to female</td><td align="left" char=" " rowspan="1" colspan="1">3 (13)</td><td align="left" char=" " rowspan="1" colspan="1">2 (11)</td></tr><tr><td align="left" colspan="4" rowspan="1">Transplant indication</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">AML</td><td align="left" char=" " rowspan="1" colspan="1">14 (58)</td><td align="left" char=" " rowspan="1" colspan="1">9 (47)</td><td align="left" char=" " rowspan="7" colspan="1">ns</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">MDS</td><td align="left" char=" " rowspan="1" colspan="1">2 (8)</td><td align="left" char=" " rowspan="1" colspan="1">1 (5)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">NHL</td><td align="left" char=" " rowspan="1" colspan="1">6 (25)</td><td align="left" char=" " rowspan="1" colspan="1">2 (11)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">HL</td><td align="left" char=" " rowspan="1" colspan="1">1 (4)</td><td align="left" char=" " rowspan="1" colspan="1">3 (16)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">CML</td><td align="left" char=" " rowspan="1" colspan="1">1 (4)</td><td align="left" char=" " rowspan="1" colspan="1">0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Myeloma</td><td align="left" char=" " rowspan="1" colspan="1">0</td><td align="left" char=" " rowspan="1" colspan="1">3 (16)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Other</td><td align="left" char=" " rowspan="1" colspan="1">0</td><td align="left" char=" " rowspan="1" colspan="1">1 (5)</td></tr><tr><td align="left" colspan="4" rowspan="1">Stem cell source</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">PBSC</td><td align="left" char=" " rowspan="1" colspan="1">18 (75)</td><td align="left" char=" " rowspan="1" colspan="1">15 (79)</td><td align="left" char=" " rowspan="2" colspan="1">ns</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">BM</td><td align="left" char=" " rowspan="1" colspan="1">6 (25)</td><td align="left" char=" " rowspan="1" colspan="1">4 (21)</td></tr><tr><td align="left" colspan="4" rowspan="1">CMV (donor/recipient)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Negative/positive</td><td align="left" char=" " rowspan="1" colspan="1">10 (42)</td><td align="left" char=" " rowspan="1" colspan="1">5 (26)</td><td align="left" char=" " rowspan="4" colspan="1">ns</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Positive/positive</td><td align="left" char=" " rowspan="1" colspan="1">5 (21)</td><td align="left" char=" " rowspan="1" colspan="1">6 (32)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Positive/negative</td><td align="left" char=" " rowspan="1" colspan="1">2 (8)</td><td align="left" char=" " rowspan="1" colspan="1">2 (11)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Negative/negative</td><td align="left" char=" " rowspan="1" colspan="1">5 (21)</td><td align="left" char=" " rowspan="1" colspan="1">6 (32)</td></tr></tbody></table><table-wrap-foot><fn id="bjh13239-note-0001"><p>FMA, fludarabine, melaphalan, alemtuzumab; SEM, standard error of the mean; AML, acute myeloid leukaemia; MDS, myelodysplastic syndrome; HNL, non&#x02010;Hodgkin lymphoma; HL, Hodgkin lymphoma; CML, chronic myeloid leukaemia; PBSC. Peripheral blood stem cells; BM, bone marrow; CMV, cytomegalovirus.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><fig fig-type="Figure" xml:lang="en" id="bjh13239-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Consort diagram summarising patients included in the study. <styled-content style="fixed-case">FMA</styled-content>: fludarabine, melphalan, alemtuzumab (dose in mg); <styled-content style="fixed-case">FLAMSA</styled-content>: fludarabine, cytarabine, amsacrine (with cyclophosphamide and total body irradiation transplant); <styled-content style="fixed-case">MUD</styled-content>, matched unrelated donor; <styled-content style="fixed-case">MMUD</styled-content>, mismatched unrelated donor (&#x0003c;9/10 antigen&#x02010;mismatched <styled-content style="fixed-case">MUD</styled-content>).</p></caption><graphic id="nlm-graphic-1" xlink:href="BJH-168-874-g001"/></fig></sec><sec id="bjh13239-sec-0010"><title>Serum Alemtuzumab levels</title><p>Serum had been collected on days +1, +3&#x02013;4 and +7 for immunomonitoring and a selection of samples was available for measurement of alemtuzumab levels. On day +1, the mean&#x000a0;&#x000b1;&#x000a0;standard deviation (SD) serum alemtuzumab level was 2&#x000b7;9&#x000a0;&#x000b1;&#x000a0;1&#x000b7;1&#x000a0;&#x003bc;g/ml in MRD transplants (30&#x000a0;mg) compared with 5&#x000b7;4&#x000a0;&#x000b1;&#x000a0;2&#x000b7;2&#x000a0;&#x003bc;g/ml in MUD transplants (60&#x000a0;mg); (<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;0002; Fig&#x000a0;<xref rid="bjh13239-fig-0002" ref-type="fig">2</xref>A). A collection of samples taken on day +3&#x02013;4 was also available to compare dose&#x02010;reduced transplants with historical patients receiving 100&#x000a0;mg alemtuzumab (Fig&#x000a0;<xref rid="bjh13239-fig-0002" ref-type="fig">2</xref>B). The serum alemtuzumab levels for both MRD and&#x000a0;MUD transplants were significantly lower with mean&#x000a0;&#x000b1;&#x000a0;SD of 2&#x000b7;3&#x000a0;&#x000b1;&#x000a0;0&#x000b7;8 and 4&#x000b7;3&#x000a0;&#x000b1;&#x000a0;1&#x000b7;8&#x000a0;&#x003bc;g/ml, respectively, compared with 8&#x000b7;2&#x000a0;&#x000b1;&#x000a0;6&#x000b7;0&#x000a0;&#x003bc;g/ml for recipients of 100&#x000a0;mg of alemtuzumab (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0&#x000b7;0028). Alemtuzumab dosing regimens in adults do not usually take into account the size of the patient but an inverse relationship was observed between alemtuzumab level and body surface area (BSA) in both cohorts, reaching significance in MRD transplants (<italic>r</italic>
<sup>2</sup>&#x000a0;=&#x000a0;0&#x000b7;70; <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0&#x000b7;0001; Fig&#x000a0;<xref rid="bjh13239-fig-0002" ref-type="fig">2</xref>C,D).</p><fig fig-type="Figure" xml:lang="en" id="bjh13239-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>(A) Comparison of mean serum alemtuzumab level on day +1 in matched related donor (<styled-content style="fixed-case">MRD</styled-content>) recipients of 30&#x000a0;mg and matched unrelated donor (<styled-content style="fixed-case">MUD</styled-content>) recipients of 60&#x000a0;mg **<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;0002. (B) Comparison of mean serum alemtuzumab level on day +3&#x02013;4 in <styled-content style="fixed-case">MRD</styled-content> recipients of 30&#x000a0;mg, <styled-content style="fixed-case">MUD</styled-content> recipients of 60&#x000a0;mg and historical controls receiving 100&#x000a0;mg alemtuzumab **<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;0028. (C) Correlation between body surface area and serum alemtuzumab in <styled-content style="fixed-case">MRD</styled-content> recipients of 30&#x000a0;mg; open symbols indicate bone marrow (<styled-content style="fixed-case">BM</styled-content>); closed symbols indicate peripheral blood stem cell (<styled-content style="fixed-case">PBSC</styled-content>) grafts. (D) Correlation between body surface area (Dubois) and serum alemtuzumab in <styled-content style="fixed-case">MUD</styled-content> recipients of 60&#x000a0;mg. Open symbols indicate <styled-content style="fixed-case">BM</styled-content>; closed symbols indicate <styled-content style="fixed-case">PBSC</styled-content> grafts.</p></caption><graphic id="nlm-graphic-3" xlink:href="BJH-168-874-g002"/></fig></sec><sec id="bjh13239-sec-0011"><title>Chimerism</title><p>Chimerism data were available for all (<italic>n</italic>&#x000a0;=&#x000a0;39) patients evaluable at day +100. Median myeloid engraftment (CD15<sup>+</sup> cells) was 100% in both cohorts (not shown). Donor T cell engraftment (CD3<sup>+</sup> cells) was significantly higher in MUD than MRD recipients (median&#x000a0;&#x000b1;&#x000a0;interquartile range: 88&#x000a0;&#x000b1;&#x000a0;33 compared with 21&#x000a0;&#x000b1;&#x000a0;46; <italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;0002; Fig&#x000a0;<xref rid="bjh13239-fig-0003" ref-type="fig">3</xref>A). As a result of treating partial T cell chimerism pre&#x02010;emptively in patients surviving more than 6&#x000a0;months, fewer MUD patients received DLI (4/19; seven doses in total) compared with MRD patients (20/24; 31 doses in total), <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0&#x000b7;0001.</p><fig fig-type="Figure" xml:lang="en" id="bjh13239-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>(A) Comparison of median peripheral blood T cell chimerism at day 100 in matched unrelated donor (<styled-content style="fixed-case">MRD</styled-content>) recipients of 30&#x000a0;mg and matched unrelated donor (<styled-content style="fixed-case">MUD</styled-content>) recipients of 60&#x000a0;mg alemtuzumab **<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;0002. (B) Incidence and severity of acute graft&#x02010;versus&#x02010;host disease (<styled-content style="fixed-case">GVHD</styled-content>) in <styled-content style="fixed-case">MRD</styled-content> recipients of 30&#x000a0;mg and <styled-content style="fixed-case">MUD</styled-content> recipients of 60&#x000a0;mg alemtuzumab; **<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0&#x000b7;0001. (C) Incidence and severity of chronic <styled-content style="fixed-case">GVHD</styled-content> in <styled-content style="fixed-case">MRD</styled-content> recipients of 30&#x000a0;mg and <styled-content style="fixed-case">MUD</styled-content> recipients of 60&#x000a0;mg alemtuzumab; **<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0&#x000b7;0001.</p></caption><graphic id="nlm-graphic-5" xlink:href="BJH-168-874-g003"/></fig></sec><sec id="bjh13239-sec-0012"><title>Graft&#x02010;versus&#x02010;host disease</title><p>Overall, 13 out of 16 (81%) MUD recipients surviving to day +100 experienced acute GVHD compared with 1 out of 23 (4%) MRD recipients, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0&#x000b7;0001. GVHD grade II or greater occurred only in MUD recipients (44% vs. 0%, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0&#x000b7;0001) (Fig&#x000a0;<xref rid="bjh13239-fig-0003" ref-type="fig">3</xref>B). Similarly, chronic GVHD was more common in MUD recipients (55% vs. 20%; <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0&#x000b7;0001) and more often extensive (Fig&#x000a0;<xref rid="bjh13239-fig-0003" ref-type="fig">3</xref>C).</p></sec><sec id="bjh13239-sec-0013"><title>Immunosuppression</title><p>Ciclosporin was tapered in the absence of GVHD from day +30. Increased GVHD in the MUD recipients was reflected by diverging mean serum ciclosporin concentrations from day +50 (Fig&#x000a0;<xref rid="bjh13239-fig-0004" ref-type="fig">4</xref>A). Overall, 13/16 (81%) MUD recipients still received ciclosporin at day +100 compared with 5/23 (22%) MRD recipients. Ciclosporin was completely withdrawn from all MRD recipients by day 128 but 7/16 (44%) MUD recipients still required immunosuppression.</p><fig fig-type="Figure" xml:lang="en" id="bjh13239-fig-0004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>(A) Comparison of mean (&#x000b1; <styled-content style="fixed-case">SEM</styled-content>) ciclosporin levels in matched related donor (<styled-content style="fixed-case">MRD</styled-content>) patients receiving 30&#x000a0;mg (dotted line) versus matched unrelated donor (<styled-content style="fixed-case">MUD</styled-content>) patients receiving 60&#x000a0;mg alemtuzumab. Significant differences between means after Bonferroni correction; **<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;0007 at day +84 and <italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;0028 at day +98. (B) Incidence of cytomegalovirus reactivation in seropositive recipients of 30&#x000a0;mg (<styled-content style="fixed-case">MRD</styled-content>) and 60&#x000a0;mg (<styled-content style="fixed-case">MUD</styled-content>) alemtuzumab, **<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0&#x000b7;0001.</p></caption><graphic id="nlm-graphic-7" xlink:href="BJH-168-874-g004"/></fig></sec><sec id="bjh13239-sec-0014"><title>Cytomegalovirus reactivation</title><p>Cytomegalovirus reactivation was seen in 15 (35%) patients overall. The reactivation rates in CMV seropositive individuals were 69% in MUD recipients and 35% in MRD recipients, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0&#x000b7;0001 (Fig&#x000a0;<xref rid="bjh13239-fig-0004" ref-type="fig">4</xref>B).</p></sec><sec id="bjh13239-sec-0015"><title>Relapse mortality, non&#x02010;relapse mortality and overall survival</title><p>Estimates for cumulative incidence of non&#x02010;relapse mortality at day +100 and 2&#x000a0;years were 4% (95% confidence interval [CI] 2&#x02013;19%) and 17% (5&#x02013;35%) for MRD recipients and 15% (4&#x02013;34%) and 20% (6&#x02013;40%) for MUD recipients (Fig&#x000a0;<xref rid="bjh13239-fig-0005" ref-type="fig">5</xref>A). The hazard ratio for NRM in MUD versus MRD recipients was 1&#x000b7;337 (95% CI 0&#x000b7;333&#x02013;5&#x000b7;370), <italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;682. Cumulative incidence of relapse at 2&#x000a0;years was 28% (11&#x02013;50%) in MRD recipients and 35% (10&#x02013;62%) in MUD recipients (Fig&#x000a0;<xref rid="bjh13239-fig-0005" ref-type="fig">5</xref>B). The hazard ratio for relapse in MUD versus MRD recipients was 1&#x000b7;116 (95% CI 0&#x000b7;353&#x02013;3&#x000b7;527), <italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;857. By Kaplan&#x02013;Meier analysis, the median survival was 804&#x000a0;d in MRD and 609 in MUD transplant recipients. Overall survival proportions at 2&#x000a0;years were 54% (31&#x02013;72%) and 45% (18&#x02013;69%) in MRD and MUD recipients, respectively (Fig&#x000a0;<xref rid="bjh13239-fig-0005" ref-type="fig">5</xref>C). The hazard ratio for death in MUD versus MRD recipients was 1&#x000b7;135 (95% CI 0&#x000b7;455&#x02013;2&#x000b7;831), <italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;785.</p><fig fig-type="Figure" xml:lang="en" id="bjh13239-fig-0005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>(A) Cumulative incidence of non&#x02010;relapse mortality. (B) Cumulative incidence of relapse. (C) Kaplan Meier curves of overall survival. Grey lines show matched related donor (<styled-content style="fixed-case">MRD</styled-content>) recipients of 30&#x000a0;mg alemtuzumab; black lines show matched unrelated donor (<styled-content style="fixed-case">MUD</styled-content>) recipients of 60&#x000a0;mg alemtuzumab. <styled-content style="fixed-case">HR</styled-content>, Hazard ratio.</p></caption><graphic id="nlm-graphic-9" xlink:href="BJH-168-874-g005"/></fig></sec></sec><sec id="bjh13239-sec-0016"><title>Discussion</title><p>The optimal dose of alemtuzumab for <italic>in vivo</italic> T cell depletion of reduced intensity conditioned transplantation is controversial and depends upon subjective judgments about the level of GVHD that tolerable or desirable, the perceived risk of relapse and the willingness of physicians to use pre&#x02010;emptive DLI to bolster post&#x02010;transplant immune reconstitution. The overall survival has been reported to be comparable between patients receiving widely ranging levels of <italic>in vivo</italic> T&#x000a0;cell depletion (Perez&#x02010;Simon <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0026" ref-type="ref">2002</xref>; Delgado <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0009" ref-type="ref">2008</xref>; van Besien <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0003" ref-type="ref">2009</xref>; Malladi <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0020" ref-type="ref">2009</xref>). The use of alemtuzumab is generally associated with higher relapse risk but less non&#x02010;relapse death and proponents argue that the quality of survivorship is improved by the prevention of extensive chronic GVHD (Perez&#x02010;Simon <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0026" ref-type="ref">2002</xref>), particularly in the T cell compartment.</p><p>Here we have evaluated 60&#x000a0;mg dosing for MUD transplants relative to the 30&#x000a0;mg dose, defined as optimal for stringent control of GVHD in MRD transplants (Chakraverty <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0008" ref-type="ref">2010</xref>). Monitoring of serum indicates that much lower levels are achieved than with 100&#x000a0;mg of alemtuzumab and that there is a predictable difference between 30&#x000a0;mg for MRD and 60&#x000a0;mg for MUD transplants, at day +1. We elected to give alemtuzumab 1&#x000a0;d earlier than Chakraverty <italic>et&#x000a0;al</italic> (<xref rid="bjh13239-bib-0008" ref-type="ref">2010</xref>), at day &#x02212;2, and the dose measured at day +1 was 30&#x02013;40% lower than that reported on day 0 by these authors (2&#x000b7;9&#x000a0;&#x003bc;g/ml for 30&#x000a0;mg and 5&#x000b7;4&#x000a0;&#x003bc;g/ml for 60&#x000a0;mg in this study compared with approximately 5 and 7&#x000b7;5&#x000a0;&#x003bc;g/ml, respectively). However, this did not appear to increase the incidence of acute GVHD grades II&#x02013;IV in our MRD cohort (both studies &#x0003c;5%). We also demonstrated a significant inverse relationship with BSA for MRD transplants and a trend in the same direction for MUD transplants. Metre&#x02010;squared dosing is common in paediatric practise (Dodero <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0010" ref-type="ref">2005</xref>; Shah <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0029" ref-type="ref">2007</xref>) and it is possible that more predictable outcomes would be observed if a similar approach was taken in adults (Morris <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0023" ref-type="ref">2003</xref>; Chakraverty <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0008" ref-type="ref">2010</xref>). The use of one 30&#x000a0;mg dose (two 30&#x000a0;mg doses for MUD transplants) in our schedule also makes economic sense, as 30&#x000a0;mg is the presentation vial size of the drug. One possible drawback is that the infusional toxicity of alemtuzumab may be higher with a single dose than with several fractionated doses, although we did not observe major difficulties with this. Prior commencement of fludarabine (day &#x02212;7) before the first dose of alemtuzumab (day &#x02212;4) may have reduced the incidence of infusional toxicity in these patients.</p><p>Our study is limited by the retrospective nature and relatively small number of patients transplanted over the period of observation. A prospective study would have been preferred but reduced alemtuzumab dosing in MUD transplants was already common practise, making a large prospective study, similar to that performed in MRD transplants, difficult to conduct. Comparison with the sibling cohort receiving 30&#x000a0;mg of alemtuzumab, rather than the historical MUD cohort receiving 100&#x000a0;mg, was motivated by the fact that sibling 30&#x000a0;mg and MUD 60&#x000a0;mg could be compared contemporaneously and that the most carefully annotated dose regime in the literature is the 30&#x000a0;mg dose given to siblings. The power of the study to detect differences in survival is rather low as indicated by wide confidence intervals in the hazard ratios. However, our primary aim was to report outcomes related to the control of GVHD. The observation that overall survival remains relatively constant with different levels of GVHD prophylaxis has been reported in several other studies (Perez&#x02010;Simon <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0026" ref-type="ref">2002</xref>; Delgado <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0009" ref-type="ref">2008</xref>; van Besien <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0003" ref-type="ref">2009</xref>; Malladi <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0020" ref-type="ref">2009</xref>).</p><p>Mixed cohorts of MRD and MUD transplant patients treated with lower doses of alemtuzumab have satisfactory outcomes overall (Faulkner <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0012" ref-type="ref">2004</xref>; Khouri <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0016" ref-type="ref">2004</xref>; Tholouli <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0032" ref-type="ref">2008</xref>; Bertz <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0002" ref-type="ref">2009</xref>; Spyridonidis <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0031" ref-type="ref">2011</xref>; Gartner <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0014" ref-type="ref">2013</xref>; Potter <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0027" ref-type="ref">2014</xref>). In a large series of 58 MRD and 69 MUD transplants subjected to a reducing regimen of 40, 20 and 10&#x000a0;mg of alemtuzumab, it was possible to infer differences between the response of MRD and MUD patients to alemtuzumab (Bertz <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0002" ref-type="ref">2009</xref>). For example, MUD transplants receiving 40&#x000a0;mg experienced 27% grade II&#x02013;IV GVHD compared with MRD patients receiving 10&#x000a0;mg who only experienced 10% grade II&#x02013;IV. This suggests that unrelated donors cause significantly more alloreactivity in this range of alemtuzumab dosing. In support of this, we found that 44% of MUD transplants experienced grade II&#x02013;IV acute GVHD after 60&#x000a0;mg of alemtuzumab compared with 0% of MRD patients after 30&#x000a0;mg of alemtuzumab. Both reports are consistent in finding more acute and chronic GVHD with MUD transplants, even when alemtuzumab dosing was increased by several fold.</p><p>In keeping with higher rates of GVHD, we observed higher donor T cell chimerism at day 100 in MUD transplants and recorded lower use of DLI compared with MRD transplants managed with the same pre&#x02010;emptive DLI policy. Higher indices of alloreactivity in MUD transplants were not due to more aggressive withdrawal of immunosuppression, as higher ciclosporin levels were maintained in these patients after day 50. Survival, relapse and non&#x02010;relapse outcomes were comparable as in other studies. One limitation of this report is that we did not record quality of life, which may have been relatively impaired in MUD transplants owing to a higher rate of extensive chronic GVHD.</p><p>Our data suggest that 60&#x000a0;mg of alemtuzumab does not achieve equivalent control of GVHD compared with 30&#x000a0;mg in MRD transplants. However, it may be na&#x000ef;ve to assume that an &#x02018;equivalent&#x02019; dose can be reached by simple titration. Review of MUD transplant patients receiving the original 100&#x000a0;mg dose indicates a 20% incidence of acute GVHD grades II&#x02013;IV (Mead <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0021" ref-type="ref">2010</xref>). Notably, this level of acute GVHD is still above that reported for MRD transplants with 30&#x000a0;mg dose (0&#x02013;5%) and only marginally increases to 22% when mismatching is permitted in unrelated donors (Mead <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0021" ref-type="ref">2010</xref>). These observations suggest that the relationship between alemtuzumab dose and antigenic disparity is non&#x02010;linear and that it may not be possible to achieve equivalent GVHD prophylaxis between MUD and MRD transplants simply by dose adjustment. Fortunately, as many studies illustrate, overall survival often remains stable despite significant variation in the burden of GVHD (Perez&#x02010;Simon <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0026" ref-type="ref">2002</xref>; Delgado <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0009" ref-type="ref">2008</xref>; van Besien <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0003" ref-type="ref">2009</xref>; Malladi <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0020" ref-type="ref">2009</xref>). Further improvements in outcome may yet be achievable by paying close attention to individualised dosing of alemtuzumab based on BSA, expression of CD52 by malignant cells and the risk of graft rejection or relapse (Khouri <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0016" ref-type="ref">2004</xref>; Chakraverty <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0008" ref-type="ref">2010</xref>; Mead <italic>et&#x000a0;al</italic>, <xref rid="bjh13239-bib-0021" ref-type="ref">2010</xref>). Attention to long&#x02010;term quality of life measurements is also paramount.</p></sec><sec id="bjh13239-sec-0018"><title>Authorship</title><p>Laura Jardine performed the research, analysed the data and wrote the paper. Amy Publicover analysed data and wrote the paper. Venetia Bigley acquired clinical data. Geoff Hale performed research and contributed data. Anne Dickinson interpreted data. Graham Jackson acquired clinical data. Matthew Collin designed the research study, analysed data and wrote the manuscript.</p></sec><sec id="bjh13239-sec-0019"><title>Conflict of interest</title><p>The authors have no conflicts of interest to declare.</p></sec></body><back><ack id="bjh13239-sec-0017"><title>Acknowledgements</title><p>This work was supported by grants from the Wellcome Trust (LJ: WT097941; VB: WT101155/Z/13/Z) and Bright Red (registered charity 1105891). The authors thank Sarah Pagan and Natasha Groves for technical assistance.</p></ack><ref-list content-type="cited-references" id="bjh13239-bibl-0001"><title>References</title><ref id="bjh13239-bib-0001"><mixed-citation publication-type="journal" id="bjh13239-cit-0001">
<string-name>
<surname>Avivi</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Chakrabarti</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Kottaridis</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Kyriaku</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Dogan</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Milligan</surname>, <given-names>D.W.</given-names>
</string-name>, <string-name>
<surname>Linch</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Goldstone</surname>, <given-names>A.H.</given-names>
</string-name> &#x00026; <string-name>
<surname>Mackinnon</surname>, <given-names>S.</given-names>
</string-name> (<year>2004</year>) <article-title>Neurological complications following alemtuzumab&#x02010;based reduced&#x02010;intensity allogeneic transplantation</article-title>. <source>Bone Marrow Transplantation</source>, <volume>34</volume>, <fpage>137</fpage>&#x02013;<lpage>142</lpage>.<pub-id pub-id-type="pmid">15235576</pub-id></mixed-citation></ref><ref id="bjh13239-bib-0002"><mixed-citation publication-type="journal" id="bjh13239-cit-0002">
<string-name>
<surname>Bertz</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Spyridonidis</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Wasch</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Grullich</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Egger</surname>, <given-names>M.</given-names>
</string-name> &#x00026; <string-name>
<surname>Finke</surname>, <given-names>J.</given-names>
</string-name> (<year>2009</year>) <article-title>A novel GVHD&#x02010;prophylaxis with low&#x02010;dose alemtuzumab in allogeneic sibling or unrelated donor hematopoetic cell transplantation: the feasibility of deescalation</article-title>. <source>Biology of Blood and Marrow Transplantation</source>, <volume>15</volume>, <fpage>1563</fpage>&#x02013;<lpage>1570</lpage>.<pub-id pub-id-type="pmid">19896080</pub-id></mixed-citation></ref><ref id="bjh13239-bib-0003"><mixed-citation publication-type="journal" id="bjh13239-cit-0003">
<string-name>
<surname>van Besien</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Kunavakkam</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Rondon</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>de Lima</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Artz</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Oran</surname>, <given-names>B.</given-names>
</string-name> &#x00026; <string-name>
<surname>Giralt</surname>, <given-names>S.</given-names>
</string-name> (<year>2009</year>) <article-title>Fludarabine&#x02010;melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long&#x02010;term outcomes</article-title>. <source>Biology of Blood and Marrow Transplantation</source>, <volume>15</volume>, <fpage>610</fpage>&#x02013;<lpage>617</lpage>.<pub-id pub-id-type="pmid">19361753</pub-id></mixed-citation></ref><ref id="bjh13239-bib-0004"><mixed-citation publication-type="journal" id="bjh13239-cit-0004">
<string-name>
<surname>Bloor</surname>, <given-names>A.J.</given-names>
</string-name>, <string-name>
<surname>Thomson</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Chowdhry</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Verfuerth</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Ings</surname>, <given-names>S.J.</given-names>
</string-name>, <string-name>
<surname>Chakraverty</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Linch</surname>, <given-names>D.C.</given-names>
</string-name>, <string-name>
<surname>Goldstone</surname>, <given-names>A.H.</given-names>
</string-name>, <string-name>
<surname>Peggs</surname>, <given-names>K.S.</given-names>
</string-name> &#x00026; <string-name>
<surname>Mackinnon</surname>, <given-names>S.</given-names>
</string-name> (<year>2008</year>) <article-title>High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non&#x02010;Hodgkin lymphoma</article-title>. <source>Biology of Blood and Marrow Transplantation</source>, <volume>14</volume>, <fpage>50</fpage>&#x02013;<lpage>58</lpage>.<pub-id pub-id-type="pmid">18158961</pub-id></mixed-citation></ref><ref id="bjh13239-bib-0005"><mixed-citation publication-type="journal" id="bjh13239-cit-0005">
<string-name>
<surname>Chakrabarti</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Mackinnon</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Chopra</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Kottaridis</surname>, <given-names>P.D.</given-names>
</string-name>, <string-name>
<surname>Peggs</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>O'Gorman</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Chakraverty</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Marshall</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Osman</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Mahendra</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Craddock</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Waldmann</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Hale</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Fegan</surname>, <given-names>C.D.</given-names>
</string-name>, <string-name>
<surname>Yong</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Goldstone</surname>, <given-names>A.H.</given-names>
</string-name>, <string-name>
<surname>Linch</surname>, <given-names>D.C.</given-names>
</string-name> &#x00026; <string-name>
<surname>Milligan</surname>, <given-names>D.W.</given-names>
</string-name> (<year>2002a</year>) <article-title>High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath&#x02010;1H in delaying immune reconstitution</article-title>. <source>Blood</source>, <volume>99</volume>, <fpage>4357</fpage>&#x02013;<lpage>4363</lpage>.<pub-id pub-id-type="pmid">12036862</pub-id></mixed-citation></ref><ref id="bjh13239-bib-0006"><mixed-citation publication-type="journal" id="bjh13239-cit-0006">
<string-name>
<surname>Chakrabarti</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Avivi</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Mackinnon</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Ward</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Kottaridis</surname>, <given-names>P.D.</given-names>
</string-name>, <string-name>
<surname>Osman</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Waldmann</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Hale</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Fegan</surname>, <given-names>C.D.</given-names>
</string-name>, <string-name>
<surname>Yong</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Goldstone</surname>, <given-names>A.H.</given-names>
</string-name>, <string-name>
<surname>Linch</surname>, <given-names>D.C.</given-names>
</string-name> &#x00026; <string-name>
<surname>Milligan</surname>, <given-names>D.W.</given-names>
</string-name> (<year>2002b</year>) <article-title>Respiratory virus infections in transplant recipients after reduced&#x02010;intensity conditioning with Campath&#x02010;1H: high incidence but low mortality</article-title>. <source>British Journal of Haematology</source>, <volume>119</volume>, <fpage>1125</fpage>&#x02013;<lpage>1132</lpage>.<pub-id pub-id-type="pmid">12472597</pub-id></mixed-citation></ref><ref id="bjh13239-bib-0007"><mixed-citation publication-type="journal" id="bjh13239-cit-0007">
<string-name>
<surname>Chakraverty</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Peggs</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Chopra</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Milligan</surname>, <given-names>D.W.</given-names>
</string-name>, <string-name>
<surname>Kottaridis</surname>, <given-names>P.D.</given-names>
</string-name>, <string-name>
<surname>Verfuerth</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Geary</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Thuraisundaram</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Branson</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Chakrabarti</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Mahendra</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Craddock</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Parker</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Hunter</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Hale</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Waldmann</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Williams</surname>, <given-names>C.D.</given-names>
</string-name>, <string-name>
<surname>Yong</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Linch</surname>, <given-names>D.C.</given-names>
</string-name>, <string-name>
<surname>Goldstone</surname>, <given-names>A.H.</given-names>
</string-name> &#x00026; <string-name>
<surname>Mackinnon</surname>, <given-names>S.</given-names>
</string-name> (<year>2002</year>) <article-title>Limiting transplantation&#x02010;related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen</article-title>. <source>Blood</source>, <volume>99</volume>, <fpage>1071</fpage>&#x02013;<lpage>1078</lpage>.<pub-id pub-id-type="pmid">11807015</pub-id></mixed-citation></ref><ref id="bjh13239-bib-0008"><mixed-citation publication-type="journal" id="bjh13239-cit-0008">
<string-name>
<surname>Chakraverty</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Orti</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Roughton</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Shen</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Fielding</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Kottaridis</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Milligan</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Collin</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Crawley</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Clark</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Parker</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Bloor</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Pettengell</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Snowden</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Pettitt</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Clark</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Hale</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Peggs</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Thomson</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Morris</surname>, <given-names>E.</given-names>
</string-name> &#x00026; <string-name>
<surname>Mackinnon</surname>, <given-names>S.</given-names>
</string-name> (<year>2010</year>) <article-title>Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA&#x02010;identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution</article-title>. <source>Blood</source>, <volume>116</volume>, <fpage>3080</fpage>&#x02013;<lpage>3088</lpage>.<pub-id pub-id-type="pmid">20587785</pub-id></mixed-citation></ref><ref id="bjh13239-bib-0009"><mixed-citation publication-type="journal" id="bjh13239-cit-0009">
<string-name>
<surname>Delgado</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Pillai</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Benjamin</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Caballero</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Martino</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Nathwani</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Lovell</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Thomson</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Perez&#x02010;Simon</surname>, <given-names>J.A.</given-names>
</string-name>, <string-name>
<surname>Sureda</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Kottaridis</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Vazquez</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Peggs</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Sierra</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Milligan</surname>, <given-names>D.</given-names>
</string-name> &#x00026; <string-name>
<surname>Mackinnon</surname>, <given-names>S.</given-names>
</string-name> (<year>2008</year>) <article-title>The effect of in vivo T cell depletion with alemtuzumab on reduced&#x02010;intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia</article-title>. <source>Biology of Blood and Marrow Transplantation</source>, <volume>14</volume>, <fpage>1288</fpage>&#x02013;<lpage>1297</lpage>.<pub-id pub-id-type="pmid">18940684</pub-id></mixed-citation></ref><ref id="bjh13239-bib-0010"><mixed-citation publication-type="journal" id="bjh13239-cit-0010">
<string-name>
<surname>Dodero</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Carrabba</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Milani</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Rizzo</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Raganato</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Montefusco</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Farina</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Milanesi</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Longoni</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Carlo&#x02010;Stella</surname>, <given-names>C.</given-names>
</string-name> &#x00026; <string-name>
<surname>Corradini</surname>, <given-names>P.</given-names>
</string-name> (<year>2005</year>) <article-title>Reduced&#x02010;intensity conditioning containing low&#x02010;dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft&#x02010;versus&#x02010;host disease is decreased but T&#x02010;cell reconstitution is delayed</article-title>. <source>Experimental Hematology</source>, <volume>33</volume>, <fpage>920</fpage>&#x02013;<lpage>927</lpage>.<pub-id pub-id-type="pmid">16038785</pub-id></mixed-citation></ref><ref id="bjh13239-bib-0011"><mixed-citation publication-type="journal" id="bjh13239-cit-0011">
<string-name>
<surname>Dubois</surname>, <given-names>D.</given-names>
</string-name> &#x00026; <string-name>
<surname>Dubois</surname>, <given-names>E.F.</given-names>
</string-name> (<year>1916</year>) <article-title>A formula to estimate the approximate surface area if height and weight be known</article-title>. <source>Archives of Internal Medicine</source>, <volume>17</volume>, <fpage>863</fpage>&#x02013;<lpage>871</lpage>.</mixed-citation></ref><ref id="bjh13239-bib-0012"><mixed-citation publication-type="journal" id="bjh13239-cit-0012">
<string-name>
<surname>Faulkner</surname>, <given-names>R.D.</given-names>
</string-name>, <string-name>
<surname>Craddock</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Byrne</surname>, <given-names>J.L.</given-names>
</string-name>, <string-name>
<surname>Mahendra</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Haynes</surname>, <given-names>A.P.</given-names>
</string-name>, <string-name>
<surname>Prentice</surname>, <given-names>H.G.</given-names>
</string-name>, <string-name>
<surname>Potter</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Pagliuca</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Ho</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Devereux</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>McQuaker</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Mufti</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Yin</surname>, <given-names>J.L.</given-names>
</string-name> &#x00026; <string-name>
<surname>Russell</surname>, <given-names>N.H.</given-names>
</string-name> (<year>2004</year>) <article-title>BEAM&#x02010;alemtuzumab reduced&#x02010;intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients</article-title>. <source>Blood</source>, <volume>103</volume>, <fpage>428</fpage>&#x02013;<lpage>434</lpage>.<pub-id pub-id-type="pmid">12969983</pub-id></mixed-citation></ref><ref id="bjh13239-bib-0013"><mixed-citation publication-type="journal" id="bjh13239-cit-0013">
<string-name>
<surname>Filipovich</surname>, <given-names>A.H.</given-names>
</string-name>, <string-name>
<surname>Weisdorf</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Pavletic</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Socie</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Wingard</surname>, <given-names>J.R.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>, <given-names>S.J.</given-names>
</string-name>, <string-name>
<surname>Martin</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Chien</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Przepiorka</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Couriel</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Cowen</surname>, <given-names>E.W.</given-names>
</string-name>, <string-name>
<surname>Dinndorf</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Farrell</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Hartzman</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Henslee&#x02010;Downey</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Jacobsohn</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>McDonald</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Mittleman</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Rizzo</surname>, <given-names>J.D.</given-names>
</string-name>, <string-name>
<surname>Robinson</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Schubert</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Schultz</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Shulman</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Turner</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Vogelsang</surname>, <given-names>G.</given-names>
</string-name> &#x00026; <string-name>
<surname>Flowers</surname>, <given-names>M.E.</given-names>
</string-name> (<year>2005</year>) <article-title>National Institutes of Health consensus development project on criteria for clinical trials in chronic graft&#x02010;versus&#x02010;host disease: I. Diagnosis and staging working group report</article-title>. <source>Biology of Blood and Marrow Transplantation</source>, <volume>11</volume>, <fpage>945</fpage>&#x02013;<lpage>956</lpage>.<pub-id pub-id-type="pmid">16338616</pub-id></mixed-citation></ref><ref id="bjh13239-bib-0014"><mixed-citation publication-type="journal" id="bjh13239-cit-0014">
<string-name>
<surname>Gartner</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Hieke</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Finke</surname>, <given-names>J.</given-names>
</string-name> &#x00026; <string-name>
<surname>Bertz</surname>, <given-names>H.</given-names>
</string-name> (<year>2013</year>) <article-title>Lowering the alemtuzumab dose in reduced intensity conditioning allogeneic hematopoietic cell transplantation is associated with a favorable early intense natural killer cell recovery</article-title>. <source>Cytotherapy</source>, <volume>15</volume>, <fpage>1237</fpage>&#x02013;<lpage>1244</lpage>.<pub-id pub-id-type="pmid">23993297</pub-id></mixed-citation></ref><ref id="bjh13239-bib-0015"><mixed-citation publication-type="journal" id="bjh13239-cit-0015">
<string-name>
<surname>Hunt</surname>, <given-names>S.C.</given-names>
</string-name>, <string-name>
<surname>Abkevich</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Hensel</surname>, <given-names>C.H.</given-names>
</string-name>, <string-name>
<surname>Gutin</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Neff</surname>, <given-names>C.D.</given-names>
</string-name>, <string-name>
<surname>Russell</surname>, <given-names>D.L.</given-names>
</string-name>, <string-name>
<surname>Tran</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Hong</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Jammulapati</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Riley</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Weaver&#x02010;Feldhaus</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Macalma</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Richards</surname>, <given-names>M.M.</given-names>
</string-name>, <string-name>
<surname>Gress</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Francis</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Thomas</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Frech</surname>, <given-names>G.C.</given-names>
</string-name>, <string-name>
<surname>Adams</surname>, <given-names>T.D.</given-names>
</string-name>, <string-name>
<surname>Shattuck</surname>, <given-names>D.</given-names>
</string-name> &#x00026; <string-name>
<surname>Stone</surname>, <given-names>S.</given-names>
</string-name> (<year>2001</year>) <article-title>Linkage of body mass index to chromosome 20 in Utah pedigrees</article-title>. <source>Human Genetics</source>, <volume>109</volume>, <fpage>279</fpage>&#x02013;<lpage>285</lpage>.<pub-id pub-id-type="pmid">11702208</pub-id></mixed-citation></ref><ref id="bjh13239-bib-0016"><mixed-citation publication-type="journal" id="bjh13239-cit-0016">
<string-name>
<surname>Khouri</surname>, <given-names>I.F.</given-names>
</string-name>, <string-name>
<surname>Albitar</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Saliba</surname>, <given-names>R.M.</given-names>
</string-name>, <string-name>
<surname>Ippoliti</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Ma</surname>, <given-names>Y.C.</given-names>
</string-name>, <string-name>
<surname>Keating</surname>, <given-names>M.J.</given-names>
</string-name> &#x00026; <string-name>
<surname>Champlin</surname>, <given-names>R.E.</given-names>
</string-name> (<year>2004</year>) <article-title>Low&#x02010;dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52&#x02010;positive malignancies: decreased incidence of acute graft&#x02010;versus&#x02010;host&#x02010;disease with unique pharmacokinetics</article-title>. <source>Bone Marrow Transplantation</source>, <volume>33</volume>, <fpage>833</fpage>&#x02013;<lpage>837</lpage>.<pub-id pub-id-type="pmid">14755312</pub-id></mixed-citation></ref><ref id="bjh13239-bib-0017"><mixed-citation publication-type="journal" id="bjh13239-cit-0017">
<string-name>
<surname>Kottaridis</surname>, <given-names>P.D.</given-names>
</string-name>, <string-name>
<surname>Milligan</surname>, <given-names>D.W.</given-names>
</string-name>, <string-name>
<surname>Chopra</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Chakraverty</surname>, <given-names>R.K.</given-names>
</string-name>, <string-name>
<surname>Chakrabarti</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Robinson</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Peggs</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Verfuerth</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Pettengell</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Marsh</surname>, <given-names>J.C.W.</given-names>
</string-name>, <string-name>
<surname>Schey</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Mahendra</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Morgan</surname>, <given-names>G.J.</given-names>
</string-name>, <string-name>
<surname>Hale</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Waldmann</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>de Elvira</surname>, <given-names>M.C.R.</given-names>
</string-name>, <string-name>
<surname>Williams</surname>, <given-names>C.D.</given-names>
</string-name>, <string-name>
<surname>Devereux</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Linch</surname>, <given-names>D.C.</given-names>
</string-name>, <string-name>
<surname>Goldstone</surname>, <given-names>A.H.</given-names>
</string-name> &#x00026; <string-name>
<surname>Mackinnon</surname>, <given-names>S.</given-names>
</string-name> (<year>2000</year>) <article-title>In vivo CAMPATH&#x02010;1H prevents graft&#x02010;versus&#x02010;host disease following nonmyeloablative stem cell transplantation</article-title>. <source>Blood</source>, <volume>96</volume>, <fpage>2419</fpage>&#x02013;<lpage>2425</lpage>.<pub-id pub-id-type="pmid">11001893</pub-id></mixed-citation></ref><ref id="bjh13239-bib-0018"><mixed-citation publication-type="journal" id="bjh13239-cit-0018">
<string-name>
<surname>Liga</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Triantafyllou</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Tiniakou</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Lambropoulou</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Karakantza</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Zoumbos</surname>, <given-names>N.C.</given-names>
</string-name> &#x00026; <string-name>
<surname>Spyridonidis</surname>, <given-names>A.</given-names>
</string-name> (<year>2013</year>) <article-title>High alloreactivity of low&#x02010;dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab&#x02010;containing conditioning regimen</article-title>. <source>Biology of Blood and Marrow Transplantation</source>, <volume>19</volume>, <fpage>75</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">22871557</pub-id></mixed-citation></ref><ref id="bjh13239-bib-0019"><mixed-citation publication-type="journal" id="bjh13239-cit-0019">
<string-name>
<surname>Mackinnon</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Barnett</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Heller</surname>, <given-names>G.</given-names>
</string-name> &#x00026; <string-name>
<surname>O'Reilly</surname>, <given-names>R.J.</given-names>
</string-name> (<year>1994</year>) <article-title>Minimal residual disease is more common in patients who have mixed T&#x02010;cell chimerism after bone marrow transplantation for chronic myelogenous leukemia</article-title>. <source>Blood</source>, <volume>83</volume>, <fpage>3409</fpage>&#x02013;<lpage>3416</lpage>.<pub-id pub-id-type="pmid">8193379</pub-id></mixed-citation></ref><ref id="bjh13239-bib-0020"><mixed-citation publication-type="journal" id="bjh13239-cit-0020">
<string-name>
<surname>Malladi</surname>, <given-names>R.K.</given-names>
</string-name>, <string-name>
<surname>Peniket</surname>, <given-names>A.J.</given-names>
</string-name>, <string-name>
<surname>Littlewood</surname>, <given-names>T.J.</given-names>
</string-name>, <string-name>
<surname>Towlson</surname>, <given-names>K.E.</given-names>
</string-name>, <string-name>
<surname>Pearce</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Yin</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Cavenagh</surname>, <given-names>J.D.</given-names>
</string-name>, <string-name>
<surname>Craddock</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Orchard</surname>, <given-names>K.H.</given-names>
</string-name>, <string-name>
<surname>Olavarria</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>McQuaker</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Collin</surname>, <given-names>M.</given-names>
</string-name> &#x00026; <string-name>
<surname>Marks</surname>, <given-names>D.I.</given-names>
</string-name> (<year>2009</year>) <article-title>Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced&#x02010;intensity conditioning sibling allo&#x02010;SCT for adults with AML</article-title>. <source>Bone Marrow Transplantation</source>, <volume>43</volume>, <fpage>709</fpage>&#x02013;<lpage>715</lpage>.<pub-id pub-id-type="pmid">19029965</pub-id></mixed-citation></ref><ref id="bjh13239-bib-0021"><mixed-citation publication-type="journal" id="bjh13239-cit-0021">
<string-name>
<surname>Mead</surname>, <given-names>A.J.</given-names>
</string-name>, <string-name>
<surname>Thomson</surname>, <given-names>K.J.</given-names>
</string-name>, <string-name>
<surname>Morris</surname>, <given-names>E.C.</given-names>
</string-name>, <string-name>
<surname>Mohamedbhai</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Denovan</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Orti</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Fielding</surname>, <given-names>A.K.</given-names>
</string-name>, <string-name>
<surname>Kottaridis</surname>, <given-names>P.D.</given-names>
</string-name>, <string-name>
<surname>Hough</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Chakraverty</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Linch</surname>, <given-names>D.C.</given-names>
</string-name>, <string-name>
<surname>Mackinnon</surname>, <given-names>S.</given-names>
</string-name> &#x00026; <string-name>
<surname>Peggs</surname>, <given-names>K.S.</given-names>
</string-name> (<year>2010</year>) <article-title>HLA&#x02010;mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab&#x02010;based reduced&#x02010;intensity conditioning</article-title>. <source>Blood</source>, <volume>115</volume>, <fpage>5147</fpage>&#x02013;<lpage>5153</lpage>.<pub-id pub-id-type="pmid">20371745</pub-id></mixed-citation></ref><ref id="bjh13239-bib-0022"><mixed-citation publication-type="journal" id="bjh13239-cit-0022">
<string-name>
<surname>Mohamedbhai</surname>, <given-names>S.G.</given-names>
</string-name>, <string-name>
<surname>Edwards</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Morris</surname>, <given-names>E.C.</given-names>
</string-name>, <string-name>
<surname>Mackinnon</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Thomson</surname>, <given-names>K.J.</given-names>
</string-name> &#x00026; <string-name>
<surname>Peggs</surname>, <given-names>K.S.</given-names>
</string-name> (<year>2012</year>) <article-title>Predominant or complete recipient T&#x02010;cell chimerism following alemtuzumab&#x02010;based allogeneic transplantation is reversed by donor lymphocytes and not associated with graft failure</article-title>. <source>British Journal of Haematology</source>, <volume>156</volume>, <fpage>516</fpage>&#x02013;<lpage>522</lpage>.<pub-id pub-id-type="pmid">22171699</pub-id></mixed-citation></ref><ref id="bjh13239-bib-0023"><mixed-citation publication-type="journal" id="bjh13239-cit-0023">
<string-name>
<surname>Morris</surname>, <given-names>E.C.</given-names>
</string-name>, <string-name>
<surname>Rebello</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Thomson</surname>, <given-names>K.J.</given-names>
</string-name>, <string-name>
<surname>Peggs</surname>, <given-names>K.S.</given-names>
</string-name>, <string-name>
<surname>Kyriakou</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Goldstone</surname>, <given-names>A.H.</given-names>
</string-name>, <string-name>
<surname>Mackinnon</surname>, <given-names>S.</given-names>
</string-name> &#x00026; <string-name>
<surname>Hale</surname>, <given-names>G.</given-names>
</string-name> (<year>2003</year>) <article-title>Pharmacokinetics of alemtuzumab used for in vivo and in vitro T&#x02010;cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications</article-title>. <source>Blood</source>, <volume>102</volume>, <fpage>404</fpage>&#x02013;<lpage>406</lpage>.<pub-id pub-id-type="pmid">12623851</pub-id></mixed-citation></ref><ref id="bjh13239-bib-0024"><mixed-citation publication-type="journal" id="bjh13239-cit-0024">
<string-name>
<surname>Peggs</surname>, <given-names>K.S.</given-names>
</string-name>, <string-name>
<surname>Thomson</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Hart</surname>, <given-names>D.P.</given-names>
</string-name>, <string-name>
<surname>Geary</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Morris</surname>, <given-names>E.C.</given-names>
</string-name>, <string-name>
<surname>Yong</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Goldstone</surname>, <given-names>A.H.</given-names>
</string-name>, <string-name>
<surname>Linch</surname>, <given-names>D.C.</given-names>
</string-name> &#x00026; <string-name>
<surname>Mackinnon</surname>, <given-names>S.</given-names>
</string-name> (<year>2004</year>) <article-title>Dose&#x02010;escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses</article-title>. <source>Blood</source>, <volume>103</volume>, <fpage>1548</fpage>&#x02013;<lpage>1556</lpage>.<pub-id pub-id-type="pmid">14576063</pub-id></mixed-citation></ref><ref id="bjh13239-bib-0025"><mixed-citation publication-type="journal" id="bjh13239-cit-0025">
<string-name>
<surname>Peggs</surname>, <given-names>K.S.</given-names>
</string-name>, <string-name>
<surname>Sureda</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Qian</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Caballero</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Hunter</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Urbano&#x02010;Ispizua</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Cavet</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Ribera</surname>, <given-names>J.M.</given-names>
</string-name>, <string-name>
<surname>Parker</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Canales</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Mahendra</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Garcia&#x02010;Conde</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Milligan</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Sanz</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Thomson</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Arranz</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Goldstone</surname>, <given-names>A.H.</given-names>
</string-name>, <string-name>
<surname>Alvarez</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Linch</surname>, <given-names>D.C.</given-names>
</string-name>, <string-name>
<surname>Sierra</surname>, <given-names>J.</given-names>
</string-name> &#x00026; <string-name>
<surname>Mackinnon</surname>, <given-names>S.</given-names>
</string-name> (<year>2007</year>) <article-title>Reduced&#x02010;intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long&#x02010;term outcomes</article-title>. <source>British Journal of Haematology</source>, <volume>139</volume>, <fpage>70</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">17854309</pub-id></mixed-citation></ref><ref id="bjh13239-bib-0026"><mixed-citation publication-type="journal" id="bjh13239-cit-0026">
<string-name>
<surname>Perez&#x02010;Simon</surname>, <given-names>J.A.</given-names>
</string-name>, <string-name>
<surname>Kottaridis</surname>, <given-names>P.D.</given-names>
</string-name>, <string-name>
<surname>Martino</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Craddock</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Caballero</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Chopra</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Garcia&#x02010;Conde</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Milligan</surname>, <given-names>D.W.</given-names>
</string-name>, <string-name>
<surname>Schey</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Urbano&#x02010;Ispizua</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Parker</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Leon</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Yong</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Sureda</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Hunter</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Sierra</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Goldstone</surname>, <given-names>A.H.</given-names>
</string-name>, <string-name>
<surname>Linch</surname>, <given-names>D.C.</given-names>
</string-name>, <string-name>
<surname>San Miguel</surname>, <given-names>J.F.</given-names>
</string-name> &#x00026; <string-name>
<surname>Mackinnon</surname>, <given-names>S.</given-names>
</string-name> (<year>2002</year>) <article-title>Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2&#x000a0;prospective studies in patients with lymphoproliferative disorders</article-title>. <source>Blood</source>, <volume>100</volume>, <fpage>3121</fpage>&#x02013;<lpage>3127</lpage>.<pub-id pub-id-type="pmid">12384408</pub-id></mixed-citation></ref><ref id="bjh13239-bib-0027"><mixed-citation publication-type="journal" id="bjh13239-cit-0027">
<string-name>
<surname>Potter</surname>, <given-names>V.T.</given-names>
</string-name>, <string-name>
<surname>Krishnamurthy</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Barber</surname>, <given-names>L.D.</given-names>
</string-name>, <string-name>
<surname>Lim</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Kenyon</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Ireland</surname>, <given-names>R.M.</given-names>
</string-name>, <string-name>
<surname>de Lavallade</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Dhouri</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Marsh</surname>, <given-names>J.C.</given-names>
</string-name>, <string-name>
<surname>Marcus</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Devereux</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Ho</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Pagliuca</surname>, <given-names>A.</given-names>
</string-name> &#x00026; <string-name>
<surname>Mufti</surname>, <given-names>G.J.</given-names>
</string-name> (<year>2014</year>) <article-title>Long&#x02010;term outcomes of alemtuzumab&#x02010;based reduced&#x02010;intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia secondary to myelodysplastic syndrome</article-title>. <source>Biology of Blood and Marrow Transplantation</source>, <volume>20</volume>, <fpage>111</fpage>&#x02013;<lpage>117</lpage>.<pub-id pub-id-type="pmid">24216184</pub-id></mixed-citation></ref><ref id="bjh13239-bib-0028"><mixed-citation publication-type="journal" id="bjh13239-cit-0028">
<string-name>
<surname>Rebello</surname>, <given-names>P.</given-names>
</string-name> &#x00026; <string-name>
<surname>Hale</surname>, <given-names>G.</given-names>
</string-name> (<year>2002</year>) <article-title>Pharmacokinetics of CAMPATH&#x02010;1H: assay development and validation</article-title>. <source>Journal of Immunological Methods</source>, <volume>260</volume>, <fpage>285</fpage>&#x02013;<lpage>302</lpage>.<pub-id pub-id-type="pmid">11792397</pub-id></mixed-citation></ref><ref id="bjh13239-bib-0029"><mixed-citation publication-type="journal" id="bjh13239-cit-0029">
<string-name>
<surname>Shah</surname>, <given-names>A.J.</given-names>
</string-name>, <string-name>
<surname>Kapoor</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Crooks</surname>, <given-names>G.M.</given-names>
</string-name>, <string-name>
<surname>Weinberg</surname>, <given-names>K.I.</given-names>
</string-name>, <string-name>
<surname>Azim</surname>, <given-names>H.A.</given-names>
</string-name>, <string-name>
<surname>Killen</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Kuo</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Rushing</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Kohn</surname>, <given-names>D.B.</given-names>
</string-name> &#x00026; <string-name>
<surname>Parkman</surname>, <given-names>R.</given-names>
</string-name> (<year>2007</year>) <article-title>The effects of Campath 1H upon graft&#x02010;versus&#x02010;host disease, infection, relapse, and immune reconstitution in recipients of pediatric unrelated transplants</article-title>. <source>Biology of Blood and Marrow Transplantation</source>, <volume>13</volume>, <fpage>584</fpage>&#x02013;<lpage>593</lpage>.<pub-id pub-id-type="pmid">17448918</pub-id></mixed-citation></ref><ref id="bjh13239-bib-0030"><mixed-citation publication-type="journal" id="bjh13239-cit-0030">
<string-name>
<surname>Shulman</surname>, <given-names>H.M.</given-names>
</string-name>, <string-name>
<surname>Sullivan</surname>, <given-names>K.M.</given-names>
</string-name>, <string-name>
<surname>Weiden</surname>, <given-names>P.L.</given-names>
</string-name>, <string-name>
<surname>McDonald</surname>, <given-names>G.B.</given-names>
</string-name>, <string-name>
<surname>Striker</surname>, <given-names>G.E.</given-names>
</string-name>, <string-name>
<surname>Sale</surname>, <given-names>G.E.</given-names>
</string-name>, <string-name>
<surname>Hackman</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Tsoi</surname>, <given-names>M.S.</given-names>
</string-name>, <string-name>
<surname>Storb</surname>, <given-names>R.</given-names>
</string-name> &#x00026; <string-name>
<surname>Thomas</surname>, <given-names>E.D.</given-names>
</string-name> (<year>1980</year>) <article-title>Chronic graft&#x02010;versus&#x02010;host syndrome in man. A long&#x02010;term clinicopathologic study of 20 Seattle patients</article-title>. <source>American Journal of Medicine</source>, <volume>69</volume>, <fpage>204</fpage>&#x02013;<lpage>217</lpage>.<pub-id pub-id-type="pmid">6996481</pub-id></mixed-citation></ref><ref id="bjh13239-bib-0031"><mixed-citation publication-type="journal" id="bjh13239-cit-0031">
<string-name>
<surname>Spyridonidis</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Liga</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Triantafyllou</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Themeli</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Marangos</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Karakantza</surname>, <given-names>M.</given-names>
</string-name> &#x00026; <string-name>
<surname>Zoumbos</surname>, <given-names>N.</given-names>
</string-name> (<year>2011</year>) <article-title>Pharmacokinetics and clinical activity of very low&#x02010;dose alemtuzumab in transplantation for acute leukemia</article-title>. <source>Bone Marrow Transplantation</source>, <volume>46</volume>, <fpage>1363</fpage>&#x02013;<lpage>1368</lpage>.<pub-id pub-id-type="pmid">21170091</pub-id></mixed-citation></ref><ref id="bjh13239-bib-0032"><mixed-citation publication-type="journal" id="bjh13239-cit-0032">
<string-name>
<surname>Tholouli</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Liakopoulou</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Greenfield</surname>, <given-names>H.M.</given-names>
</string-name>, <string-name>
<surname>Shaw</surname>, <given-names>B.E.</given-names>
</string-name>, <string-name>
<surname>Tauro</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Byrne</surname>, <given-names>J.L.</given-names>
</string-name>, <string-name>
<surname>Dennis</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Burthem</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Lucas</surname>, <given-names>G.S.</given-names>
</string-name>, <string-name>
<surname>Craddock</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Russell</surname>, <given-names>N.H.</given-names>
</string-name> &#x00026; <string-name>
<surname>Liu Yin</surname>, <given-names>J.A.</given-names>
</string-name> (<year>2008</year>) <article-title>Outcomes following 50&#x000a0;mg versus 100&#x000a0;mg alemtuzumab in reduced&#x02010;intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia</article-title>. <source>British Journal of Haematology</source>, <volume>142</volume>, <fpage>318</fpage>&#x02013;<lpage>320</lpage>.<pub-id pub-id-type="pmid">18492100</pub-id></mixed-citation></ref><ref id="bjh13239-bib-0033"><mixed-citation publication-type="journal" id="bjh13239-cit-0033">
<string-name>
<surname>Thomson</surname>, <given-names>K.J.</given-names>
</string-name>, <string-name>
<surname>Morris</surname>, <given-names>E.C.</given-names>
</string-name>, <string-name>
<surname>Milligan</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Parker</surname>, <given-names>A.N.</given-names>
</string-name>, <string-name>
<surname>Hunter</surname>, <given-names>A.E.</given-names>
</string-name>, <string-name>
<surname>Cook</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Bloor</surname>, <given-names>A.J.</given-names>
</string-name>, <string-name>
<surname>Clark</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Kazmi</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Linch</surname>, <given-names>D.C.</given-names>
</string-name>, <string-name>
<surname>Chakraverty</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Peggs</surname>, <given-names>K.S.</given-names>
</string-name> &#x00026; <string-name>
<surname>Mackinnon</surname>, <given-names>S.</given-names>
</string-name> (<year>2010</year>) <article-title>T&#x02010;cell&#x02010;depleted reduced&#x02010;intensity transplantation followed by donor leukocyte infusions to promote graft&#x02010;versus&#x02010;lymphoma activity results in excellent long&#x02010;term survival in patients with multiply relapsed follicular lymphoma</article-title>. <source>Journal of Clinical Oncology</source>, <volume>28</volume>, <fpage>3695</fpage>&#x02013;<lpage>3700</lpage>.<pub-id pub-id-type="pmid">20606089</pub-id></mixed-citation></ref></ref-list></back></article>